GeoVax Labs Inc
Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.
period unavailable · Filed Aug 6, 2024
GOVX$0.16-0.1%Stored close · as of Nov 6, 2026
Contents
Preclinical Development Programs
| Product | Indication | Status |
|---|---|---|
| GEO-MVA-MUC1 | Solid Tumor Cancers | Humanized Mouse Model (completed) |
| GEO-CM02 | Pan-Coronavirus Vaccine | Humanized Mouse Model (completed) |
| GEO-EM01-Z | Ebola Zaire Vaccine** | Non-Human Primate (completed) |
| GEO-EM01-S | Ebola Sudan Vaccine** | Non-Human Primate (completed) |
| GEO-MM01 | Marburg Vaccine** | Non-Human Primate (completed) |
| GEO-ZM02 | Zika Vaccine** | Mouse Model (completed) |
| GEO-MVA | Mpox & Smallpox Vaccine | Regulatory Discussions & Manufacturing Scale-up |
** Orphan Drug status granted*
*** Indication within FDA Priority Review Voucher program*
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.